BioNTech
BNTX
Performance
About BioNTech
BioNTech SE is a biotechnology company developing immunotherapies and mRNA vaccines to improve health worldwide. It focuses on oncology with a diversified pipeline including mRNA cancer immunotherapies, immunomodulators, and targeted therapies, as well as programs in infectious diseases. The company emphasizes scientific rigor, innovation, and collaboration to advance therapies from research to clinical use. Headquartered in Mainz, Germany, BioNTech operates globally to address cancer, infectious diseases, and other serious illnesses.
Recent News
Portugal: Will the Life Science Sector See Upswing Amid Funding Worries?
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
Pfizer, BioNTech to Pause COVID Vaccine Study Due to Low Enrollment
This Pill May Help Pancreatic Cancer Patients Live Longer
What’s in a Name? Moderna’s “Vaccine” Vs. “Therapy” Dilemma
Dr. Vinay Prasad Said He Would Deliver New COVID Vaccine RCTs. He Failed and Should STFU.
Pfizer Makes $530M Vaccine Play With Novavax Deal After Rumors of BioNTech Pullback
Modern Relay Raises $3M to Build Shared Infrastructure Layer for AI Agents in the Enterprise
Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB
BioNTech, UPenn Team up for $50M Seed Fund
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
DualityBio Reports China NMPA Acceptance of BLA for Trastuzumab Pamirtecan in Metastatic HER2+ Breast Cancer
Poland, Romania Ordered to Honor Vaccine Deal with Pfizer
BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline
Momentum Builds for Local Drug Production
Pfizer, BioNTech Abort U.S. Updated COVID-19 Vaccine Trial as Enrollment Falters
BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
BioNTech's HER2 ADC Succeeds in Phase 2 Study, FDA Filing Planned
BioNTech Reports Promising Phase II Data for Uterine Cancer ADC
Once More Into the Valley of Death: Navigating SBIR/STTR Funding for Tech Startups After 2025
U.S. Vaccine Approvals to Undergo Overhaul: What Do the Changes Mean?
MRNA Pioneer Katalin Karikó to Give Johns Hopkins Commencement Address
JPM: AbbVie Pays $650m Upfront for RemeGen Cancer Drug
GSK Delivers in New CEO Miels' First Financial Update
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
Pfizer, BioNTech Drop Updated COVID‑19 Vaccine Study After Low Enrollment
BioNTech Cofounders To Step Down. Stock Crumbles.
Recent Deals
No recent deals for this company.
